108 related articles for article (PubMed ID: 12089783)
61. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
62. Adenoid cystic carcinoma of the trachea and bronchus--a clinicopathologic study with DNA flow cytometric analysis and oncogene expression.
Lin CM; Li AF; Wu LH; Wu YC; Lin FC; Wang LS
Eur J Cardiothorac Surg; 2002 Oct; 22(4):621-5. PubMed ID: 12297183
[TBL] [Abstract][Full Text] [Related]
63. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
Lee JS; Kim HS; Jung JJ; Kim YB; Lee MC; Park CS
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):289-95. PubMed ID: 12607595
[TBL] [Abstract][Full Text] [Related]
64. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.
Pupa SM; Bufalino R; Invernizzi AM; Andreola S; Rilke F; Lombardi L; Colnaghi MI; Ménard S
J Clin Oncol; 1996 Jan; 14(1):85-94. PubMed ID: 8558226
[TBL] [Abstract][Full Text] [Related]
65. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
66. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
67. Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?
Beltràn M; Colomer R
J Clin Oncol; 2002 Dec; 20(23):4605; author reply 4606. PubMed ID: 12454123
[No Abstract] [Full Text] [Related]
68. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
69. Pathobiologic characteristics of hereditary breast cancer.
Lynch BJ; Holden JA; Buys SS; Neuhausen SL; Gaffney DK
Hum Pathol; 1998 Oct; 29(10):1140-4. PubMed ID: 9781655
[TBL] [Abstract][Full Text] [Related]
70. Systematic review of HER2 breast cancer testing.
Cuadros M; Villegas R
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):1-7. PubMed ID: 18685491
[TBL] [Abstract][Full Text] [Related]
71. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.
Arens N; Bleyl U; Hildenbrand R
Virchows Arch; 2005 May; 446(5):489-96. PubMed ID: 15838646
[TBL] [Abstract][Full Text] [Related]
72. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
73. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
74. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
[TBL] [Abstract][Full Text] [Related]
75. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues.
Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K
J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273
[TBL] [Abstract][Full Text] [Related]
76. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
77. Immunohistochemical and molecular markers in breast phyllodes tumors.
Korcheva VB; Levine J; Beadling C; Warrick A; Countryman G; Olson NR; Heinrich MC; Corless CL; Troxell ML
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):119-25. PubMed ID: 21030860
[TBL] [Abstract][Full Text] [Related]
78. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
79. Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
Bot FJ; Sleddens HF; Dinjens WN
Diagn Mol Pathol; 1998 Dec; 7(6):295-301. PubMed ID: 10207667
[TBL] [Abstract][Full Text] [Related]
80. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
